Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Dobson

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 27, 2022
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentaryRuth Dobson, Karen Chung
Neurology|July 1, 2021
Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?Ruth Dobson, Amber Salter
Practical Neurology|March 25, 2016
The difficulties with vitamin B12Ruth Dobson, Debie Alvares
Current Opinion in Neurology|March 12, 2021
Use of disease-modifying drugs during pregnancy and breastfeedingRuth Dobson, Kerstin Hellwig
Antibodies (Basel, Switzerland)|May 28, 2024
Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic ManagementPanagiotis Gklinos, Ruth Dobson
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical GuidePanagiotis Gklinos, Ruth Dobson
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2025
Navigating pregnancy in women with NMOSD in the monoclonal antibody eraWallace J Brownlee, Ruth Dobson
Neurology|April 15, 2020
Breastfeeding may reduce postpartum relapse in some women with multiple sclerosisRuth Dobson, Ellen M Mowry
Neurology|March 11, 2020
Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosisVilija G Jokubaitis, Ruth Dobson
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2020
Family planning is the second most relevant factor for treatment decisions after disease activity - CommentaryVilija G Jokubaitis, Ruth Dobson
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 27, 2022
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentaryRuth Dobson, Karen Chung
Neurology|July 1, 2021
Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?Ruth Dobson, Amber Salter
Practical Neurology|March 25, 2016
The difficulties with vitamin B12Ruth Dobson, Debie Alvares
Current Opinion in Neurology|March 12, 2021
Use of disease-modifying drugs during pregnancy and breastfeedingRuth Dobson, Kerstin Hellwig
Antibodies (Basel, Switzerland)|May 28, 2024
Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic ManagementPanagiotis Gklinos, Ruth Dobson
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical GuidePanagiotis Gklinos, Ruth Dobson
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2025
Navigating pregnancy in women with NMOSD in the monoclonal antibody eraWallace J Brownlee, Ruth Dobson
Neurology|April 15, 2020
Breastfeeding may reduce postpartum relapse in some women with multiple sclerosisRuth Dobson, Ellen M Mowry
Neurology|March 11, 2020
Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosisVilija G Jokubaitis, Ruth Dobson
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 22, 2020
Family planning is the second most relevant factor for treatment decisions after disease activity - CommentaryVilija G Jokubaitis, Ruth Dobson
Pageof 19